Rocky Mountain Movement Disorders Center | Englewood, CO
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The primary goal of this study is to evaluate the safety and pharmacodynamic effects of PTC518 compared with placebo in participants with HD.
Full description
Participants will first be randomized to Part A or Part B or Parts D or E in a 1:1 randomization ratio, depending on their Huntington's disease Integrated Staging System (HD-ISS) staging criteria and then to active treatment (PTC518 5 mg in Parts A and D and 10 mg in Parts B and E) or matching placebo within each part in a 2:1 ratio of active treatment to placebo. A Drug Safety Monitoring Board (DSMB) Charter will undertake an unblinded review of safety data from the 5 and 10 mg dosing groups and provide a recommendation on when Parts C and F (with a 20 mg active treatment arm) can be initiated. At that time, participants will be randomized to any study Part that is currently open for enrollment, and then to either active treatment or placebo (in a 2:1 ratio) within that Part.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Key Inclusion Criteria:
Eligibility for HD-ISS Stage 2 Group (Parts A, B, and C):
Eligibility for HD-ISS Mild Stage 3 Group (Parts D, E, and F):
Key Exclusion Criteria:
Note: Other inclusion and exclusion criteria may apply.
Primary purpose
Allocation
Interventional model
Masking
252 participants in 4 patient groups, including a placebo group
Loading...
Central trial contact
Patient Advocacy
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal